Here's What Drove Bristol-Myers Earnings

Author:
Publish date:
Video Duration:
1:08

Bristol-Myers Squibb  (BMY) - Get Bristol-Myers Squibb Company Report posted earnings on Thursday, Feb. 6. 

Here's what drove the quarter.

Bristol-Myers Squibb said that non-GAAP earnings came in at $1.22 a share, which was well ahead of analysts' expectations of 94 cents and up 30% from the same period last year.

Revenue came in at $7.95 billion, which beat expectations of $6.2 billion.

And then the company forecasts non-GAAP earnings of $6 to $6.20 a share, with revenue rising to between $40.5 and $42.5 billion in the financial year of 2020.

Sales of Opdivo, which is Bristol-Myers blockbuster Immuno-oncology drug, fell 2% to $1.76 billion, which came in shy of the FactSet consensus of $1.79 billion.

And Bristol-Myers noted that it “progressed our strategy through the acquisition of Celgene.”

Watch the video above for more.

Online real estate platform CrowdStreet delivers investors a new way to diversify their portfolios with real estate. Individual investors can use CrowdStreet’s leading online marketplace to connect with a wide array of commercial real estate opportunities and projects to make investing in real estate easy! Download the Real Estate Guide.

Catch up on the Latest Videos on TheStreet!

Related Videos